vs

Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and Knowles Corp (KN). Click either name above to swap in a different company.

Knowles Corp is the larger business by last-quarter revenue ($153.1M vs $85.1M, roughly 1.8× 4D Molecular Therapeutics, Inc.). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs 6.3%, a 16.5% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs 22.7%). 4D Molecular Therapeutics, Inc. produced more free cash flow last quarter ($28.5M vs $-3.1M). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs -13.5%).

4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.

Knowles Corporation is a global leading designer and manufacturer of advanced micro-acoustic, audio processing, and precision component solutions. It serves core segments including consumer electronics, automotive, medical technology, and industrial markets, offering products such as MEMS microphones, hearing aid components, and edge audio processing ICs to worldwide clients.

FDMT vs KN — Head-to-Head

Bigger by revenue
KN
KN
1.8× larger
KN
$153.1M
$85.1M
FDMT
Growing faster (revenue YoY)
FDMT
FDMT
+8508877.3% gap
FDMT
8508900.0%
22.7%
KN
Higher net margin
FDMT
FDMT
16.5% more per $
FDMT
22.8%
6.3%
KN
More free cash flow
FDMT
FDMT
$31.6M more FCF
FDMT
$28.5M
$-3.1M
KN
Faster 2-yr revenue CAGR
FDMT
FDMT
Annualised
FDMT
5412.6%
-13.5%
KN

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
FDMT
FDMT
KN
KN
Revenue
$85.1M
$153.1M
Net Profit
$19.4M
$9.7M
Gross Margin
43.8%
Operating Margin
17.3%
10.4%
Net Margin
22.8%
6.3%
Revenue YoY
8508900.0%
22.7%
Net Profit YoY
139.1%
585.0%
EPS (diluted)
$0.43
$0.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FDMT
FDMT
KN
KN
Q1 26
$153.1M
Q4 25
$85.1M
$162.2M
Q3 25
$90.0K
$152.9M
Q2 25
$15.0K
$145.9M
Q1 25
$14.0K
$132.2M
Q4 24
$1.0K
$142.5M
Q3 24
$3.0K
$142.5M
Q2 24
$5.0K
$204.7M
Net Profit
FDMT
FDMT
KN
KN
Q1 26
$9.7M
Q4 25
$19.4M
$21.0M
Q3 25
$-56.9M
$17.4M
Q2 25
$-54.7M
$7.8M
Q1 25
$-48.0M
$-2.0M
Q4 24
$18.5M
Q3 24
$-43.8M
$500.0K
Q2 24
$-35.0M
$-259.3M
Gross Margin
FDMT
FDMT
KN
KN
Q1 26
43.8%
Q4 25
44.7%
Q3 25
45.7%
Q2 25
41.5%
Q1 25
40.3%
Q4 24
42.7%
Q3 24
44.1%
Q2 24
28.2%
Operating Margin
FDMT
FDMT
KN
KN
Q1 26
10.4%
Q4 25
17.3%
15.9%
Q3 25
-67983.3%
16.9%
Q2 25
-396373.3%
10.1%
Q1 25
-383007.1%
3.0%
Q4 24
10.8%
Q3 24
-1704400.0%
13.1%
Q2 24
-849120.0%
6.2%
Net Margin
FDMT
FDMT
KN
KN
Q1 26
6.3%
Q4 25
22.8%
12.9%
Q3 25
-63195.6%
11.4%
Q2 25
-364386.7%
5.3%
Q1 25
-342657.1%
-1.5%
Q4 24
13.0%
Q3 24
-1461433.3%
0.4%
Q2 24
-699060.0%
-126.7%
EPS (diluted)
FDMT
FDMT
KN
KN
Q1 26
$0.13
Q4 25
$0.43
$0.23
Q3 25
$-1.01
$0.20
Q2 25
$-0.98
$0.09
Q1 25
$-0.86
$-0.02
Q4 24
$0.20
Q3 24
$-0.79
$0.01
Q2 24
$-0.63
$-2.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FDMT
FDMT
KN
KN
Cash + ST InvestmentsLiquidity on hand
$402.7M
$41.0M
Total DebtLower is stronger
$131.0M
Stockholders' EquityBook value
$505.7M
$780.2M
Total Assets
$566.7M
$1.1B
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FDMT
FDMT
KN
KN
Q1 26
$41.0M
Q4 25
$402.7M
$54.2M
Q3 25
$305.1M
$92.5M
Q2 25
$293.2M
$103.2M
Q1 25
$321.4M
$101.9M
Q4 24
$424.9M
$130.1M
Q3 24
$501.9M
$92.6M
Q2 24
$541.9M
$84.0M
Total Debt
FDMT
FDMT
KN
KN
Q1 26
$131.0M
Q4 25
$114.0M
Q3 25
$176.3M
Q2 25
$190.0M
Q1 25
$188.8M
Q4 24
$202.5M
Q3 24
$225.0M
Q2 24
$261.2M
Stockholders' Equity
FDMT
FDMT
KN
KN
Q1 26
$780.2M
Q4 25
$505.7M
$775.8M
Q3 25
$369.0M
$751.8M
Q2 25
$420.9M
$746.1M
Q1 25
$469.7M
$755.8M
Q4 24
$510.6M
$756.0M
Q3 24
$552.9M
$777.4M
Q2 24
$588.3M
$753.0M
Total Assets
FDMT
FDMT
KN
KN
Q1 26
$1.1B
Q4 25
$566.7M
$1.1B
Q3 25
$424.0M
$1.1B
Q2 25
$473.6M
$1.1B
Q1 25
$515.7M
$1.1B
Q4 24
$560.4M
$1.1B
Q3 24
$604.0M
$1.2B
Q2 24
$620.1M
$1.2B
Debt / Equity
FDMT
FDMT
KN
KN
Q1 26
0.17×
Q4 25
0.15×
Q3 25
0.23×
Q2 25
0.25×
Q1 25
0.25×
Q4 24
0.27×
Q3 24
0.29×
Q2 24
0.35×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FDMT
FDMT
KN
KN
Operating Cash FlowLast quarter
$28.6M
$0
Free Cash FlowOCF − Capex
$28.5M
$-3.1M
FCF MarginFCF / Revenue
33.5%
-2.0%
Capex IntensityCapex / Revenue
0.1%
7.1%
Cash ConversionOCF / Net Profit
1.47×
0.00×
TTM Free Cash FlowTrailing 4 quarters
$-109.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FDMT
FDMT
KN
KN
Q1 26
$0
Q4 25
$28.6M
Q3 25
$-46.5M
$29.1M
Q2 25
$-43.4M
$36.4M
Q1 25
$-47.8M
$1.3M
Q4 24
$-134.6M
Q3 24
$-29.4M
$52.8M
Q2 24
$-30.2M
$24.9M
Free Cash Flow
FDMT
FDMT
KN
KN
Q1 26
$-3.1M
Q4 25
$28.5M
Q3 25
$-46.6M
$21.4M
Q2 25
$-43.4M
$31.3M
Q1 25
$-48.4M
$-2.7M
Q4 24
$-138.4M
Q3 24
$-31.2M
$49.1M
Q2 24
$-30.6M
$21.7M
FCF Margin
FDMT
FDMT
KN
KN
Q1 26
-2.0%
Q4 25
33.5%
Q3 25
-51765.6%
14.0%
Q2 25
-289620.0%
21.5%
Q1 25
-345635.7%
-2.0%
Q4 24
-13837100.0%
Q3 24
-1038966.7%
34.5%
Q2 24
-611840.0%
10.6%
Capex Intensity
FDMT
FDMT
KN
KN
Q1 26
7.1%
Q4 25
0.1%
9.4%
Q3 25
101.1%
5.0%
Q2 25
440.0%
3.5%
Q1 25
4507.1%
3.0%
Q4 24
378600.0%
2.3%
Q3 24
59266.7%
2.6%
Q2 24
6980.0%
1.6%
Cash Conversion
FDMT
FDMT
KN
KN
Q1 26
0.00×
Q4 25
1.47×
Q3 25
1.67×
Q2 25
4.67×
Q1 25
Q4 24
Q3 24
105.60×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons